French-based SERB Pharmaceuticals, a global specialty pharmaceutical company with an office in West Conshohocken, recently announce its Aurlumyn Injection is now commercially available in the United States.
The drug is the first treatment for severe frostbite in adults at risk of digit amputations that the U.S. Food and Drug Administration (FDA) has approved.
“We are proud to make Aurlumyn available to hospitals, first responders, and military customers in the U.S.,” Thomas Kolaras, SERB Pharmaceuticals executive vice president and U.S. chief commercial officer, said. “This treatment empowers healthcare professionals to act decisively in critical moments, delivering hope and effective care to those at risk of life-altering complications.”
Annually, thousands of people are hospitalized with frostbite in the United States. It can cause digit or limb necrosis requiring amputation. Aurlumyn is a drug that opens blood vessels and inhibits platelet aggregation. It is recommended for grades 3 and 4 frostbite and is effective up to 72 hours after a patient’s rewarming begins.
The FDA approved the drug in February and also granted it priority review and the orphan drug designation.
SERB Pharmaceuticals formally launched Aurlumyn at the American Society of Health-System Pharmacists Midyear Clinical Meeting & Exhibition in New Orleans from Dec. 8-12.